Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PolyPhetamine (ITL Health Group)
- Development stage
- Preclinical
- Lead developer
- ITL Pharma
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
PolyPhetamine is a polymer-drug conjugate being developed by ITL Pharma for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The drug utilizes a proprietary delivery technology where amphetamine is chemically bonded to a polymer backbone, creating a prodrug that requires enzymatic or physiological cleavage for activation. This design is intended to provide a smooth, extended-release pharmacokinetic profile and reduce the potential for drug abuse, as the stimulant cannot be easily extracted or rapidly released through non-oral routes. Once released, the amphetamine moiety acts by increasing synaptic concentrations of dopamine and norepinephrine through the stimulation of trace amine-associated receptor 1 (TAAR1) and the inhibition of the dopamine and norepinephrine transporters.
- Other names
- PolyPhetamine-ITL Pharma-ADHD
02
Targets
TAAR1 (Trace amine-associated receptor 1)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on PolyPhetamine (ITL Health Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PolyPhetamine (ITL Health Group).